XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative (NQ:XOMAO)

25.34 -0.02 (-0.08%)

Streaming Delayed Price Updated: 10:16 AM EDT, May 29, 2026 Add to My Watchlist

Price and Volume

Volume	321
Open	25.34
Bid (Size)	25.33 (2,400)
Ask (Size)	25.37 (400)
Prev. Close	25.36
Today's Range	25.34 - 25.34
52wk Range	24.86 - 26.40
Shares Outstanding	N/A
Dividend Yield	8.26%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (NASDAQ:XOMAO) Surges as a Top Growth Stock Candidate Under Navellier's Little Book Strategy ↗

May 13, 2026

Via Chartmill

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

April 27, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

Performance

YTD	+0.2%	+0.2%
1 Month	+0.6%	+0.6%
3 Month	-0.3%	-0.3%
6 Month	-0.5%	-0.5%
1 Year	+0.3%	+0.3%

More News

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (NASDAQ:XOMAO) Checks All Eight Boxes in Navellier’s Little Book Growth Screen ↗

April 22, 2026

Via Chartmill

XOMA Royalty Corp (NASDAQ:XOMAO) Stands Out in a High-Growth Stock Screen ↗

April 01, 2026

Via Chartmill

XOMA Royalty Declares Quarterly Preferred Stock Dividends

March 18, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

March 18, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

March 12, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Present at Investor Conferences in March

February 18, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

February 09, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces CFO Transition

January 12, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

December 30, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

December 22, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

December 05, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

November 21, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

November 12, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

October 17, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

October 02, 2025

From XOMA Royalty Corporation; LAVA Therapeutics

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

September 22, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

September 17, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 03, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

August 20, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

August 04, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

August 04, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Frequently Asked Questions

Is XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative publicly traded?

Yes, XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is publicly traded.

What exchange does XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative trade on?

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative trades on the Nasdaq Stock Market

What is the ticker symbol for XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative?

The ticker symbol for XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is XOMAO on the Nasdaq Stock Market

What is the current price of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative?

The current price of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is 25.34

When was XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative last traded?

The last trade of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative was at 05/29/26 10:16 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.